Semaglutide may have slightly higher rates of these effects in clinical trials, likely reflecting its greater potency
The most likely explanation relates to metabolic changes induced by these medications
DOI: 10.3389/fendo.2024.1431292 [Google Scholar] Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al
Either outcome will directly impact BPI Labs ability to continue producing compounded semaglutide at scale
As a general principle, fewer ingredients means fewer unknown interactions, so a two-peptide blend involves less combinatorial uncertainty than a four-peptide one but that is not the same as being safe. A large, separate risk is product quality: these are unregulated research chemicals, and independent testing across the market has found mislabeled, underdosed, or contaminated products
Methods Using a high-fat dietinduced obesity mouse model, we investigated the effects of Retatrutide on adipose tissue through integrated physiological, histological, transcriptomic, and metabolomic analyses